医学
他汀类
内科学
队列
心肌梗塞
需要治疗的数量
人口
动脉粥样硬化性心血管疾病
物理疗法
冲程(发动机)
弗雷明翰风险评分
低风险
疾病
心脏病学
相对风险
置信区间
环境卫生
工程类
机械工程
作者
Maria García-Gil,Marc Comas‐Cufí,Jordi Blanch,Ruth Martí‐Lluch,Anna Ponjoan,Lia Alves‐Cabratosa,Irene Petersen,Jaume Marrugat,Roberto Elosúa,María Grau,Rafel Ramos
摘要
The purpose was to analyze statin effectiveness in a general population with differing levels of coronary heart disease (CHD) risk. Patients (35–74 years) without previous cardiovascular disease were included and stratified according to 10‐year CHD risk (<5%, 5–7.4%, 7.5–9.9%, and 10–19.9%). New users were categorized according to their medical possession ratio (MPR). The main outcome was atherosclerotic cardiovascular disease (ASCVD) (myocardial infarction and ischemic stroke). In adherent patients (MPR 70%), statin treatment decreased ASCVD risk across the range of coronary risk (from 16–30%). The 5‐year number needed to treat (NNT) was 470 and 204 in the risk categories <5% and 5–7.4%, respectively, and 75 and 62 in the 7.5–9.9% category than in the 10–19.9% category, respectively. Statin therapy should remain a priority in patients at high 10‐year CHD risk (10–19.9%). Most patients with intermediate risk could benefit from statin treatment, but the treatment decision should focus on the net benefit, safety, and patient preference, given the higher NNT.
科研通智能强力驱动
Strongly Powered by AbleSci AI